

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**School of Medical and Allied Sciences**

Bachelor of Pharmacy

Semester End Examination - May 2024

Duration : 180 Minutes

Max Marks : 75

**Sem VIII - BPET8004 - Pharmaceutical Regulatory Science**General Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- 1) Recall IRB K1 (2)
- 2) Explain supplemental NDA. K2 (2)
- 3) What is protocol template? K1 (2)
- 4) Illustrate DCGI K2 (2)
- 5) What is NDA? K1 (2)
- 6) Infer reference biological agent. K2 (2)
- 7) Define sponsors for clinical trials. K1 (2)
- 8) Infer ADRs. K2 (2)
- 9) Recall lead identification. K1 (2)
- 10) Infer CTD K2 (2)
  
- 11) Construct a note on post-market drug safety monitoring. K3 (5)

**OR**

- Construct a note on Innovator drug product. K3 (5)
  
- 12) Assume table of contents of Federal Register. K4 (5)
- 13) Construct a note on GCP obligations with respect to sponsors. K3 (5)
- 14) Categorize the Metadata fields and values of federal register. K4 (5)
- 15) Construct a note on GCP obligations with respect to investigators. K3 (5)
  
- 16) Analyze the DCGI timelines for the IND approval process. K4 (5)

**OR**

- Analyze the types of drug applications submitted to SLA. K4 (5)
- 17) Simplify the contents of purple book. K4 (5)
- 18) Discuss the CFR in pharmaceuticals. K6 (10)
  
- 19) Conclude the regulatory approval process of generic drug product. K5 (10)

**OR**

- Conclude a note on generic drug product development. K5 (10)